Pharmacokinetics of oral tizanidine, a CYP1A2 substrate, in Mexicans: Evidence for interethnic variability

Trial Profile

Pharmacokinetics of oral tizanidine, a CYP1A2 substrate, in Mexicans: Evidence for interethnic variability

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Tizanidine (Primary)
  • Indications Muscle spasticity
  • Focus Pharmacokinetics
  • Most Recent Events

    • 15 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top